Monterey

Researchers are evaluating the safety and effectiveness of combining ruxolitinib, steroids, and lenalidomide in patients with relapsed or refractory multiple myeloma (MM) who show disease progression. Multiple myeloma is a cancer of plasma cells in the bone marrow, and despite advances in treatment, it remains incurable. This phase 1, open-label, multicenter study aims to explore new therapeutic options by targeting the JAK/STAT pathway involved in MM cell growth and survival. Participants will receive oral ruxolitinib daily on days 1 through 28, lenalidomide on days 1 through 21, and methylprednisolone daily on days 1 through 28 of each treatment cycle. The combination therapy is being studied to determine the maximum tolerated dose of ruxolitinib when used with steroids and lenalidomide. The study also monitors treatment-emergent adverse events over a period of up to 54 months. Throughout the study, participants will undergo various assessments including laboratory tests to monitor blood counts, liver and kidney function, and disease markers. Researchers will evaluate safety, tolerability, and efficacy by tracking adverse events and disease progression. Participants must be able to follow the study schedule and provide informed consent. The study also involves registration in the REVLIMID REMS program for safety monitoring related to lenalidomide use.

This research aims to collect detailed and standardized data from adult patients receiving routine cancer care at participating oncology centers. The study is observational and focuses on gathering information about patients, their treatments, and outcomes to support research and development in oncology. Patient surveys are also part of the data collection process to enrich the information gathered. Since this is an observational registry, there are no specific treatments or interventions provided by the study. Instead, it collects data on standard care treatments administered at the participating centers. The registry includes baseline patient information, treatment patterns, safety data, and treatment effectiveness over time. Participants will provide informed consent and contribute data through regular surveys and medical records. Researchers will monitor treatment effectiveness by tracking the time until treatment discontinuation. The study collects and analyzes data continuously, aiming to facilitate more patient involvement in clinical trials and improve cancer care research. Eligible adults may participate for as long as they continue routine care at the centers.

Researchers are evaluating patients with advanced or metastatic non-small cell lung cancer (NSCLC) to create control arms using current and future treatment information. This prospective study aims to generate precise external controls for patients receiving therapies recommended by the National Comprehensive Cancer Network (NCCN). The focus is on patients treated in second or third line with NCCN-approved systemic therapies. Participants must have pathologically confirmed NSCLC and an Eastern Cooperative Oncology Group (ECOG) performance status greater than 1, indicating they are fit for further systemic therapy. Eligible patients are those starting or within 14 days of starting second line therapy according to NCCN guidelines. The study monitors patients over time to assess treatment responses and outcomes. During the study, researchers assess the objective response rate (ORR) by patient cohort from September 2025 to April 2029. Participants are followed closely with imaging and clinical evaluations to ensure compliance with study protocols. Safety and life expectancy of more than three months are considered to support ongoing participation and data collection.

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy). The planned duration of treatment in either arm of the study is 7 years. Eligible patients must have intermediate-high or high risk of recurrence as defined by specified clinical and biologic criteria. Concurrent use of abemaciclib is permitted in both arms. The primary endpoint of the study is Invasive breast cancer-free survival (IBCFS) and main secondary endpoints include Invasive disease-free survival (IDFS), Distant relapse-free survival (DRFS), Overall survival (OS), Safety and Clinical Outcome Assessments (COAs). Patients will be followed for 10 years from randomization of the last patient.

This trial compares two supportive cancer care delivery methods for adults with newly diagnosed or recurrent solid tumor cancers. The purpose is to evaluate which approach better improves health-related quality of life and other patient-centered outcomes such as patient activation, satisfaction with care, documentation of goals, and reduction in acute care. It is a cluster-randomized comparative effectiveness study involving multiple sites assigned to different care models. One group receives technology-based supportive cancer care with weekly electronic messages or emails providing information on advance care planning and symptom management during the first four months, then every other week up to 12 months. The other group is paired with a lay health worker who discusses the same educational materials either in person or by telephone on the same schedule. Both groups receive ongoing support over the year-long intervention. Participants complete a baseline interview at enrollment and follow-up surveys at 3, 6, and 12 months. Researchers assess changes in health-related quality of life using the Functional Assessment of Cancer Therapy (FACT-G) from baseline to 3 months as the primary outcome. Secondary outcomes include patient activation, satisfaction with care, documentation of care goals, acute care use, and palliative or hospice care utilization. The study monitors participants for one year to evaluate these outcomes.

Researchers are evaluating surgical and minimally invasive treatments for lumbar spinal stenosis (LSS) by comparing Medicare patients who received the MILD procedure against those who had interspinous process decompression (IPD). The study focuses on outcomes such as the rate of harms related to the initial procedure and the frequency of additional surgical or minimally invasive interventions within 24 months after treatment. Enrollment includes patients treated from January 1, 2017, onward, with continuation until the sponsor decides to stop. The MILD procedure involves percutaneous image-guided lumbar decompression, performed under fluoroscopy through a dorsal approach to partially remove tissue and bone at the affected spinal level. The control group receives the IPD procedure for LSS. Both groups are monitored for a 24-month period post-index procedure using Medicare claims data to track reoperations and any harms. Participants contribute data through Medicare claims without needing prior enrollment or consent, as the study is exempt from IRB oversight. Researchers collect and analyze information on procedure-related harms and subsequent interventions over two years. This approach allows evaluation of long-term safety and effectiveness outcomes for patients treated with either MILD or IPD.

Researchers are creating a prospective cohort of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that has common EGFR mutations. The study focuses on patients diagnosed on or after January 1st, 2024, and aims to collect standardized clinical data at key points: before treatment begins, during treatment, and when treatment ends. About 30% of patients who join before starting osimertinib therapy will have imaging done at regular intervals to monitor their condition. The study involves patients receiving first-line osimertinib treatment for their advanced NSCLC. Although specific interventions are not detailed, the study tracks progression-free survival from when treatment starts until the disease worsens or the patient passes away, with assessments continuing for up to 100 months. This long-term follow-up allows researchers to observe how the cancer progresses in a real-world setting under this treatment. Participants will undergo standardized data collection including imaging and clinical evaluations at baseline, during treatment, and at therapy discontinuation. Researchers will monitor progression-free survival as the primary outcome. Eligibility is based on diagnosis details and treatment history, with exclusion for certain prior therapies and poor performance status. The study includes adults aged 18 years and older and will gather detailed information over an extended period to better understand treatment outcomes in this patient population.